Amantadine for fatigue in multiple sclerosis

Evidence Summaries

Level of Evidence = D

There is insufficient evidence on the efficacy of amantadine in reducing fatigue in people with MS.

A Cochrane review 1 included 5 studies (1 parallel arms, 4 crossover trials) with a total of 272 subjects. Quality of the studies was generally poor and all trials were open to bias. All studies reported small and inconsistent improvements in fatigue, whereas the clinical relevance of these findings and the impact on patient's functioning and health related quality of life remained undetermined. The number of participants reporting side effects during amantadine therapy ranged from 10% to 57%.

Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison), by limitations in study quality and by inconsistency (variability in results across studies).

References

1. Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007 Jan 24;(1):CD002818.  [PMID:17253480]


Copyright © 2017 Duodecim Medical Publications Limited.
Amantadine for fatigue in multiple sclerosis is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Amantadine for fatigue in multiple sclerosis ID - 453058 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/453058/all/Amantadine_for_fatigue_in_multiple_sclerosis PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -